BCLI - Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
2024-07-08 10:12:09 ET
Brainstorm Cell Therapeutics Inc. (BCLI)
Corporate Mid-Year Update on NurOwn Program
July 8, 2024 8:00 AM ET
Company Participants
Joyce Lonergan - LifeSci Advisors
Chaim Lebovits - President and Chief Executive Officer
Haro Hartounian - Executive Vice President, Chief Operating Officer
Bob Dagher - Executive Vice President, Chief Medical Officer
Conference Call Participants
Jason McCarthy - Maxim Group
David Bautz - Zachs Small Cap Research
Presentation
Operator
Greetings and welcome to the Brainstorm Cell Therapeutics Mid-Year 2024 Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded.
And I would now like to introduce your host for today's call, Joyce Lonergan of LifeSci Advisors. Ms. Lonergan, you may begin.
Joyce Lonergan
Thank you, Holly. Good morning, and thank you for joining us today. Before passing the call off to company management for prepared remarks, I would like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential for future business operations and performance. Statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS; the sufficiency of the company's existing capital resources for continuing operations in 2024 and beyond; the safety and clinical efficacy of the NurOwn technology platform; clinical trials of NurOwn and related clinical development programs; and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts....
Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)